Effect of ayurvedic medicine -Hansapadadi Kashay Ghan tablet and Gandamala Kandan Rasa along with Katutumbi Taila Nasya in hypothyroidism.

EFFICACY OF HANSAPADADI KASHAY GHAN TABLET WITH KATUTUMBI TAILA NASYA IN COMPARISON TO GANDAMALA KANDAN RASA ALONG WITH KATUTUMBI TAILA NASYA IN THE MANAGEMENT OF HYPOTHYROIDISM- A RANDOMISED CONTROLLED CLINICAL STUDY - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/109629

Enrollment

120

Registered

2026-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. TSH levels greater than or equal to 5.6mIU/L to less than or equal to 14.9mIU/L 2. Patients having signs and symptoms of Hypothyroidism i.e., weight gain, cold intolerance, fatigue, dry skin, dry hair, menorrhagia, constipation, hoarseness of voice, alopecia, aches and pains, muscle stiffness, deafness, depression, infertility, psychosis, periorbital edema, anaemia, bradycardia, hypertension. 3. Nasya Arha 4. Patient taking constant dose conventional treatment since last 6 weeks and willing to switch to ayurveda treatment. 5. Patients having classical symptoms of medo dhtvagnimandya according to Ayurveda ( through Agni assessment proforma ).

Exclusion criteria

Exclusion criteria: 1. Patients having TSH level greater than 14.9mIU/L 2. Recent thyroid surgery (within 12 months) 3. Subjects having any other comorbidities or systemic illness such as uncontrolled DMT2(RBS greater than 300mg/dl), Uncontrolled HTN (greater than or equal to 160/100mm Hg), cardiovascular disease, stroke, pulmonary disease, tuberculosis, psychiatric illness, HIV, Encephalopathy, Goiter, Other endocrine disorders, and other autoimmune disorders 4. Subject suffering from any hepatic disorder (SGPT and SGOT more than three times the upper limit of normal). 5. Subjects suffering from chronic kidney disease or any renal disorder (serum creatinine greater than 1.2 mg/dL). 6. Lactating and pregnant women.

Design outcomes

Primary

Measure	Time frame
Change in Serum TSH Level from baseline. Timepoint: Day 0 DAY 42 Day 70	—

Secondary

Measure	Time frame
Change in T3 and T4. Timepoint: Day 0, Day 42;Change in Clinical Score for hypothyroidism . Timepoint: Day 0, Day 42;Change in health-related quality of life assessed through ThyPRO questionnaire from baseline.Timepoint: Day 0, Day 42;Change in BMI & Lipid profile from baseline. Timepoint: Day 0, Day 42;Incidence of adverse events, if any.Timepoint: Day 0, Day 42;Change in the laboratory safety parameters (LFT, KFT) from baseline. Timepoint: Day 0, Day 42	—

Measure

Time frame

Change in T3 and T4. Timepoint: Day 0, Day 42;Change in Clinical Score for hypothyroidism . Timepoint: Day 0, Day 42;Change in health-related quality of life assessed through ThyPRO questionnaire from baseline.Timepoint: Day 0, Day 42;Change in BMI & Lipid profile from baseline. Timepoint: Day 0, Day 42;Incidence of adverse events, if any.Timepoint: Day 0, Day 42;Change in the laboratory safety parameters (LFT, KFT) from baseline. Timepoint: Day 0, Day 42

—

Countries

India

Contacts

Public ContactDr Rashmi Tokas Rana

ALL INDIA INSTITUTE OF AYURVEDA

jonahdr@gmail.com9448262298

Outcome results